07:00 , Jul 25, 2005 |  BC Week In Review  |  Company News

Guilford, MGI deal

MOGN will acquire GLFD for $3.75 per share, or $177.5 million in stock and cash. The price is a 56% premium to GLFD's close of $2.41 on July 20, before the deal was announced. MOGN...
01:11 , Jul 22, 2005 |  BC Extra  |  Top Story

MGI to acquire Guilford

MOGN will acquire GLFD for $3.75 per share, or $177.5 million in stock and cash. The price is a 56% premium to GLFD's close of $2.41 on Wednesday, before the deal was announced. MOGN will...
08:00 , Mar 30, 2004 |  BC Extra  |  Company News

Pfizer returns pain compounds to GLFD

PFE returned to Guilford (GLFD) rights to develop and commercialize NAALADase inhibitors. Under a May 2003 deal, PFE licensed exclusive rights to the class of compounds. The deal included a $5 million payment to Guilford...
07:00 , May 12, 2003 |  BC Week In Review  |  Company News

Guilford, Pfizer deal

PFE received exclusive worldwide rights to a class of n-acetylated-alpha-linked-acidic-dipeptidase ( NAALADase ) inhibitors from GLFD to treat neurodegenerative diseases. Under the deal, PFE will be responsible for all R&D and marketing costs of the...
07:00 , May 12, 2003 |  BioCentury  |  Finance

Ebb & Flow

For the past few years, the major focus for investors in Neurobiological Technologies (NTII) has been on its Memantine , which is marketed in Europe for Alzheimer's disease and is awaiting U.S. approval for the...
07:00 , May 8, 2003 |  BC Extra  |  Company News

Guilford, Pfizer neurology deal

PFE received exclusive worldwide rights to a class of n-acetylated-alpha-linked-acidic-dipeptidase ( NAALADase ) inhibitors from GLFD to treat neurodegenerative diseases. PFE will be responsible for all R&D and marketing costs of the inhibitors, which are...
08:00 , Dec 18, 2000 |  BC Week In Review  |  Clinical News

GPI-5693: Began Phase I trial

Guilford Pharmaceuticals Inc. (GLFD), Baltimore, Md.   Product: GPI-5693   Business: Neurological   Therapeutic category: Neuroprotectant   Target: NAALADase   Description: Inhibitor of N-acetylated alpha-linked acidic dipeptidase   Indication: Treat neuropathic pain   Status: GLFD...
08:00 , Nov 13, 2000 |  BC Week In Review  |  Clinical News

Guilford preclinical data

GLFD said its inhibitors of NAALADase, which modulates the release of glutamate, reversed disease progression and provided symptomatic relief of peripheral neuropathy in mice. The compounds also were effective in relieving neuropathic pain at lower...
08:00 , Nov 1, 1999 |  BC Week In Review  |  Clinical News

Guilford preclinical data

GLFD researchers reported that the company's NAALADase inhibitors induced the production of myelin, repaired damage and reversed the symptoms of diabetic neuropathy in rats. Data were presented at the Society for Neuroscience meeting in Miami...
07:00 , May 10, 1999 |  BC Week In Review  |  Clinical News

Guilford regulatory update

GLFD received four U.S. Patents. Nos. 5,859,031 and 5,874,449 cover small molecule FKBP-neuroimmunophilin ligands to treat and prevent neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. Nos. 5,863,536 and 5,880,112 cover small molecule NAALADase...